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Purpose: Although some CDH13 single nucleotide polymorphisms (SNPs) have 
been shown to be determinants of blood adiponectin levels, the clinical implica-
tions of CDH13 variants are not yet completely understood. The purpose of this 
study was to evaluate the effects of SNPs of CDH13 on metabolic and vascular 
phenotypes. Materials and Methods: We included 238 hypertensive subjects and 
260 age- and sex-matched controls. Seven tagging-SNPs were identified in the 
CDH13 gene by whole gene sequencing. The association between these SNP vari-
ants and the risk of hypertension, metabolic traits, and carotid intima-media thick-
ness (IMT) was examined. Results: Minor allele carriers of rs12444338 had a 
lower risk of hypertension, but the association turned out just marginal after ad-
justing confoudners. Blood glucose levels were higher in the minor allele carriers 
of c.1407C>T (p=0.01), whereas low-density lipoprotein-cholesterol levels were 
greater in those of rs6565105 (p=0.02). The minor allele of rs1048612 was associ-
ated with a higher body mass index (p=0.01). In addition, the mean carotid IMT 
was significantly associated with rs12444338 (p=0.02) and rs1048612 (p=0.02). 
Conclusion: These results provide evidence that CDH13 variants are associated 
with metabolic traits and carotid atherosclerosis in Koreans. This study shows the 
multifaceted effects of CDH13 variants on cardiometabolic risk.
Key Words:   CDH13 protein, human, hypertension, atherosclerosis, glucose, cho-
lesterol
INTRODUCTION
CDH13 has been reported to encode T-cadherin, an adiponectin receptor discov-
ered after adipoR1 and adipoR2.1 It is characteristically expressed on vascular 
cells such as endothelial cells and smooth muscle cells.2 Prior experimental studies 
suggested that T-cadherin modulates tissue and circulating adiponectin levels, 
therefore affecting vascular remodeling, inflammation, and atherosclerosis.1,3,4 
However, the role of T-cadherin in adiponectin signaling into the cells and its clini-
cal implication is not completely understood. 
Asian people exhibit the characteristic phenotype of adiposity5 and adiposity-re-
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Exclusion criteria were structural heart disease, coronary 
artery disease, secondary hypertension, diabetes mellitus, or 
serum creatinine >1.4 mg/dL. This study was conducted 
under the approval of the local Institutional Review Board. 
Clinical data, blood samples, and carotid IMT
On the day of enrollment, clinical data including demograph-
ic variables and medical history were recorded. Venous 
blood samples were collected after an overnight fast and 
samples were analyzed within 4 hours of collection. All 
analyses were conducted by a local laboratory, certified by 
the Korean Society of Laboratory Medicine. 
Carotid IMT was measured as a surrogate marker of ath-
erosclerosis. This examination was only available for study 
subjects enrolled in the registry in the last 3 years. A longitudi-
nal B-mode image of common carotid arteries was obtained 
by 8-MHz linear scanner (Sequoia C512, Acuson Co Ltd., 
Oceanside, CA, USA) and stored digitally. The mean carotid 
IMT of the far walls of the common carotid arteries were 
measured 1 cm proximal to the carotid bifurcation on the end-
diastolic frame using an automated edge-detection method 
program (M’ATH, METRIS Co., Argenteuil, France). 
Sequencing and genotyping
PCR primers were designed to independently amplify 
CDH13 fragments. Primer sequences are available on re-
quest. PCR products were purified and then sequenced us-
ing a BigDye Terminator Cycle Sequencing Kit (version 
3.1, ABI, Foster City, CA, USA) and ABI 3730×1 automat-
ed sequencer (Applied Biosystems, Foster City, CA, USA). 
The sequencing primers were the same as those used for 
PCR amplification. Mutation analyses were conducted us-
ing Phred, Pharp, Consed, Polyphred 5.04 software (http://
droog.mbt.washington.edu/PolyPhred.html). 
Seven tagging-SNPs identified in the CDH13 gene by 
whole gene sequencing were genotyped. Genomic DNA was 
extracted from 5 mL of peripheral venous blood using a 
commercially available isolation kit (QuickGene SP Kit 
DNA whole blood, Fujifilm, Tokyo, Japan). Genotyping was 
performed using the TaqMan fluorogenic 5’ nuclease assay 
(ABI). 
Statistical analysis
Group differences for categorical variables were assessed 
by chi-square test and continuous variables were examined 
by Student’s t-test. The association between genotype and 
hypertension was evaluated using odds ratios (ORs) and 
lated lipid6 or vascular traits.5 However, studies on genetic 
basis of these relationships have been insufficient in this 
population. To date, several CDH13 single nucleotide poly-
morphisms (SNPs) including rs3865188 have been shown 
to be determinants of blood adiponectin levels in Asians.7-9 
The association between rs11646213, a CDH13 SNP, and 
blood pressure phenotype has also been reported in Europe-
an cohorts.10 Chung, et al.11 demonstrated that rs4783244, 
another SNP, is associated with the metabolic syndrome 
phenotype in Taiwanese. Although they provided possible 
evidence of a relationship with CDH13-cardiometabolic 
disease, the association between the variant and hyperten-
sion was not clear. 
Here we examined the effect of seven SNPs of the CDH13 
gene on cardiometabolic traits in a cohort of 498 Koreans. 
The purpose of the study was to evaluate the association be-
tween the seven SNPs and hypertension risk, metabolic 
traits, and carotid atherosclerosis. In the current study, we 
found an associations between rs12444338 and hypertension, 
which was marginal, and carotid intima-media thickness 
(IMT). Another CDH13 SNP, rs1048612, was found to be 
related to body mass index and carotid IMT. We also found 
two more SNPs that are associated with blood glucose and 
cholesterol levels. Our study shows the multifaceted effect of 




Two hundred thirty-eight unrelated Korean subjects with 
hypertension and 260 age- and sex-matched healthy control 
subjects were recruited for this study. Subjects were drawn 
from the Cardiovascular Genome Center Registry from Yon-
sei University Health System. Briefly, consecutive subjects 
who visited Severance Cardiovascular Hospital in Seoul, 
Korea were prospectively screened for hypertension using 
several inclusion criteria. Subjects who had systolic blood 
pressure (BP) ≥135 mm Hg and/or diastolic BP ≥85 mm Hg 
during three different visits before taking antihypertensive 
medications or who were already taking such medications 
were recruited. Hypertensive subjects who were diagnosed at 
30-60 years of age were eligible for the study. Two hundred 
sixty unrelated Koreans without a diagnosis of hypertension 
were recruited from Cardiology Clinic in the same hospital. 
Control subjects had to have a systolic BP <135 mm Hg and 
diastolic BP <85 mm Hg without taking BP-lowering agents. 
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rs72807847, rs6565105, and rs1048612. The minor allele 
frequencies were 0.027-0.394 for each SNP (Table 2). 
Association between studied variants and hypertension, 
metabolic traits, and carotid atherosclerosis
One SNP, rs12444338, was significantly associated with 
hypertension. In the first additive model, that adjusted for 
age and sex, the TT genotype of SNP was associated with a 
decreased risk of hypertension [OR=0.74 (CI 0.56-0.98), 
p=0.03] (Table 2). However, in model 2 after further adjust-
ment for metabolic variables, the association was only mar-
ginally significant. No other associations were observed be-
tween the genotypes of other SNPs and hypertension risk. 
In further examinations of the variants with other meta-
bolic traits, blood glucose levels increased with the number 
of C alleles in c.1407C>T SNP (p=0.01). In addition, the 
AA genotype of rs6565105 showed higher LDL-C levels 
(p=0.02), whereas the AA genotype of rs1048612 was asso-
ciated with higher body mass index (p=0.01) (Table 3). 
The mean carotid IMT decreased with the number of T 
allele of rs12444338 in the additive model (p=0.02). The 
AA genotype of rs1048612 was associated with greater 
IMT, compared to the GG or GA genotype of the SNP 
(p=0.02) (Fig. 1, Supplementary Table 1). 
Haplotypes of SNPs of rs6565051-rs7204454 and those 
of rs6565051-rs7204454-C_1407T-rs12444338-rs72807847-
rs6565105 were evaluated. Two combinations were associ-
ated with body mass index, another one with glucose levels, 
and another one with carotid IMT (Supplementary Table 2). 
These findings further provide potential additive effects of 
SNPs of CDH13, although exploration of the corresponding 
95% confidence intervals (CIs) from chi-square tests and 
logistic regression analyses. Possible genotype-related dif-
ferences in other cardiometabolic traits such as body mass 
index, blood glucose, triglyceride, low-density lipoprotein-
cholesterol (LDL-C), and carotid IMT values were ana-
lyzed by Kruskal-Wallis test. The recessive model tested 
the association of having one homozygous risk allele (1) vs. 
having at least one non-risk allele in homozygous (0) or in 
heterozygous (0). The additive model tested the association 
that depend additively upon the risk or minor allele, 0 for 
homozygous non-risk alleles, 1 for heterozygous alleles 
and 2 for homozygous risk alleles. We estimated our power 
to detect the association. For minor allele frequencies of 
0.3-0.4, our study had 80% power to detect odds ratios as 
small as 1.44-1.46. In these analyses, 33-38 outliers by 
standard quartile method were excluded. Results are ex-
pressed as mean±SD or median (interquartile range) and p 
values were computed from each model of association. All 





Characteristics of the study population
Characteristics of the case-control population are shown in 
Table 1. The median age was 51 years and females made up 
50% of the population. Cases had higher body mass index, 
blood glucose, and triglyceride levels, but lower high-den-
sity lipoprotein-cholesterol levels. The seven tagging-SNPs 
were rs6565051, rs7204454, c.1407C>T, rs12444338, 
Table 1. Characteristics of the Study Subjects
 Total (n=498) Normotensive (n=260) Hypertensive (n=238) p value
Age, yrs    51 (45-56)    51 (45-57)    50 (45-55) 0.40
Female  249 (50)  129 (50)  120 (50) 0.86
Body mass index, kg/m2 22.8 (21.7-24.1) 22.5 (21.5-23.8) 23.2 (22.2-24.4)  <0.001†
Waist circumference, cm    82 (77-87)    81 (77-86)    83 (78-88)  <0.001†
Metabolic syndrome  136 (27)    44 (17)    92 (37)  <0.001†
Laboratory values, mg/dL
    Glucose    83 (78-91)    82 (78-89)    85 (78-94) 0.03
    Total cholesterol  198 (175-222)  199 (175-225)  196 (175-220) 0.31
    Triglycerides  111 (82-167)  103 (77-158)  122 (85-180)   0.01*
    HDL-C    48 (40-59)    50 (42-60)    47 (38-58)   0.02*
    LDL-C  120 (101-142)  122 (102-146)  118 (100-139) 0.15
HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol. 
Values are median (interquartile range) or n (%).
*p<0.05. 
†p<0.01.
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SNPs, such as c.1407C>T and rs6565105, were associated 
with metabolic traits including blood glucose and cholester-
ol levels, respectively. Our study shows the multifaceted ef-
fects of CDH13 variants on metabolic and vascular traits. 
Recently, an association between a SNP of CDH13 and 
blood pressure was identified and replicated in Europeans. 
In that report, carriers of the minor allele of rs11646213 had 
a decreased risk of hypertension.10 In another ethnic group, 
CDH13 variants also had an effect on blood pressure, but 
top SNPs were different from the prior study.12 In our study, 
rs12444338 variants demonstrated a marginal association 
with hypertension risk. This SNP is located in the promoter 
mechanism was beyond the purpose of our study.
DISCUSSION
The current study demonstrates no significant association 
between SNP located within CDH13 and hypertension in 
Koreans. Only marginal association was observed between 
rs12444338 and hypertension. We demonstrated that a mi-
nor allele of this SNP imparted a thinner carotid IMT. In ad-
dition, rs1048612, which showed an association with body 
mass index, also had an effect on carotid IMT. Other CDH13 






OR (95% CI) 
p value
Additive model 
OR (95% CI) 
p value
Model 1
    rs6565051 A/G 0.355 1.39 (0.82-2.37) 0.22 1.08 (0.84-1.41) 0.55
    rs7204454 G/C 0.366 1.07 (0.65-1.75) 0.80 0.91 (0.70-1.17) 0.44
    c.1407C>T T/C 0.027 - - 0.88 (0.40-1.94) 0.93
    rs12444338 G/T 0.309 0.53 (0.27-1.03) 0.06 0.74 (0.56-0.98)   0.03*
    rs72807847 A/G 0.038 - - 0.79 (0.40-1.56) 0.50
    rs6565105 G/A 0.394 1.10 (0.67-1.80) 0.70 1.02 (0.79-1.32) 0.89
    rs1048612 G/A 0.182 1.75 (0.66-4.61) 0.26 1.04 (0.75-1.43) 0.83
Model 2
    rs6565051 1.40 (0.79-2.48) 0.25 1.11 (0.83-1.47) 0.48
    rs7204454 1.21 (0.70-2.09) 0.50 0.95 (0.73-1.26) 0.73
    c.1407C>T - - 0.88 (0.40-1.94) 0.93
    rs12444338 0.60 (0.29-1.24) 0.17 0.77 (0.57-1.05) 0.09
    rs72807847 - - 0.81 (0.38-1.73) 0.59
    rs6565105 1.03 (0.60-1.78) 0.92 0.98 (0.74-1.30) 0.88
    rs1048612 1.26 (0.44-3.60) 0.66 0.95 (0.67-1.34) 0.76
MAF, minor allele frequency; OR, odds ratio; SNP, single nucleotide polymorphism; CI, confidence interval; HDL-C, high-density lipoprotein-cholesterol; 
LDL-C, low-density lipoprotein-cholesterol. 
The p value and ORs were calculated with multivariate logistic regression analysis with adjustment for age, sex (model 1), or age, sex, body mass index, 
waist circumference, glucose, triglyceride, HDL-C, and LDL-C (model 2). 
*p<0.05.
















GG GGGT GATT AAGG+GT GG+GATT AA
rs12444338 rs1048612
p=0.02 p=0.22p=0.15 p=0.02
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tivity of CDH13 may suggest this variant can play a role in 
CDH13 regulation and phenotypic change.7
We found associations between two SNPs, rs12444338 
region of CDH13.7,13 It is not clear how rs12444338 affects 
the blood pressure phenotype; however, the association of 
rs12444338 polymorphisms and the changed promoter ac-
Table 3. Association between Genotype of Studied Variants and Metabolic Traits
Traits
Numbers









    AA 198 23.0 (21.7-24.3) 85 (78-91) 112 (82-175)   119 (101-141)
    GA 204 22.8 (21.9-24.2) 82 (78-89) 109 (82-156)   121 (101-143)
    GG   58 22.6 (21.4-23.9) 85 (80-96) 119 (88-162)   124 (102-147)
    pa 0.27 0.08 0.50 0.68
    pb 0.55 0.19 0.30 0.59
 rs7204454
    GG 188 22.9 (21.3-24.2) 82 (78-91) 111 (85-162) 119 (99-143)
    GC 200 22.8 (21.8-24.1) 83 (78-90) 108 (81-163)   124 (101-145)
    CC   72 22.9 (21.3-24.2) 85 (78-92) 118 (81-181)   112 (102-138)
    pa 0.59 0.49 0.49 0.46
    pb 0.57 0.69 0.45 0.28
c.1407C>T
    TT 443 22.8 (21.7-24.2) 83 (78-90) 111 (82-162)   120 (101-142)
    CT   22 22.4 (21.6-23.7) 87 (80-98) 126 (89-179)   119 (110-139)
    CC     1 24.8 (24.8-24.8)   110 (110-110)   160 (160-160)   181 (181-181)
    pa 0.15 0.10 0.41 0.10
    pb 0.42 0.01 0.77 0.18
rs12444338
    GG 208 22.8 (21.8-23.8) 82 (78-90) 112 (85-160)   121 (102-143)
    GT 210 22.8 (21.8-24.1) 84 (78-91) 111 (83-171)   121 (101-143)
    TT   41 23.0 (21.0-24.0) 85 (76-91) 106 (77-163)   114 (101-141)
    pa 0.55 0.78 0.74 0.71
    pb 0.31 0.75 0.84 0.91
rs72807847
    AA 428 22.8 (21.7-24.2) 83 (78-91) 111 (83-163)   121 (101-143)
    GA   35 22.7 (21.6-23.9) 86 (78-95) 112 (80-165) 115 (99-132)
    GG     0 - - - -
    pa - - - -
    pb 0.74 0.46 0.85 0.31
rs6565105
    GG 171 22.7 (21.7-24.0) 83 (78-91) 117 (86-173) 115 (99-138)
    GA 221 22.9 (21.9-24.2) 83 (78-90) 106 (82-160)   120 (100-142)
    AA   72 22.8 (21.6-24.2) 85 (80-91) 110 (82-163)   128 (109-147)
    pa 0.91 0.24 0.91   0.02*
    pb 0.45 0.29 0.38 0.09
rs1048612
    GG 312 22.8 (21.8-24.2) 84 (78-90) 111 (82-164)   121 (102-143)
    GA 131 22.8 (21.5-24.0) 83 (78-91) 108 (82-162) 114 (99-142)
    AA   18 23.7 (23.1-24.3) 83 (80-96)   130 (100-162)   124 (101-135)
    pa   0.01* 0.41 0.31 0.43
    pb 0.08 0.52 0.78 0.24
LDL-C, low-density lipoprotein-cholesterol; pa, p value of recessive model; pb, p value of additive model; SNP, single nucleotide polymorphism.
Values are median (interquartile range).
*p<0.05.
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and rs1048612 and carotid IMT. The effect of rs12444338 
was significant on additive and dominant models and seems 
to be influenced by heterozygote subjects. However, the as-
sociation was not obvious in the recessive model; therefore, 
further confirmation in a larger population is needed. Al-
though it was previously reported that another SNP of 
CDH13, rs4783244, is associated with carotid IMT and 
stroke risk,11 this is the first time that these two SNPs have 
shown an effect on vascular phenotype. Traditional cardio-
vascular risk factors, including age, sex, hypertension, smok-
ing, hypercholesterolemia, and body mass index, have been 
reported as determinants of carotid IMT.14,15 The effect of 
rs12444338 on blood pressure and that of rs1048612 on 
body mass index were identified in our results, and these 
findings are concordant to the association of the two SNP 
and carotid IMT. CDH13-encoded T-cadherin, when ligated, 
can activate nuclear factor-κB signaling and promote inflam-
mation.16 Furthermore, T-cadherin expression is associated 
with vascular smooth muscle cell proliferation.4 These bio-
logical functions may be possible processes linking CDH13 
variant and carotid atherosclerosis. However, CDH13 has 
been ranked as having the highest number of interaction part-
ners17 and the mechanism of the effects of CDH13 variants 
on carotid atherosclerosis may be more complex than we 
now estimate.
In our study, carriers of a minor allele of c.1407C>T had 
higher glucose levels, whereas those of rs6565105 had 
higher LDL-C levels. This is the first report to uncover an 
association between these two SNPs and metabolic traits. 
As previously mentioned, the CDH13 gene is a strong de-
terminant of blood adiponectin level, and this level is corre-
lated with various metabolic traits including glucose levels, 
insulin levels, and dyslipidemia.18 Therefore, the associa-
tion between the c.1407C>T variant and glucose may be 
partly mediated by an adiponectin-related mechanism. The 
rs4783244 genotype of CDH13 was found to be correlated 
to glucose levels, as well as triglyceride levels or abdominal 
obesity, in Asians.11 Similarly, in a Swedish cohort, Fava, et 
al.19 demonstrated that the CDH13 rs11645213 T>A poly-
morphism is associated with metabolic syndrome. On the 
other hand, T-cadherin, coded by CDH13, was reported to 
modulate signaling and cellular response to insulin;20 this re-
port is also in accordance with our results. The relationship 
between CDH13 variants and cholesterol level has not been 
well established. However, Dong, et al.21 recently demon-
strated that two SNPs of CDH13, rs4357934 and rs1164264, 
were significantly associated with total and LDL-C levels. 
Supplementary Table 1. Association between Studied Vari-






    AA 39 0.736±0.101
    GA 30 0.758±0.097
    GG 14 0.752±0.092
    pa 0.83
    pb 0.64
 rs7204454
    GG+GC 40 0.748±0.087
    GC 32 0.746±0.109
    CC 11 0.743±0.100
    pa 0.91
    pb 0.99
c.1407C>T
    TT 76 0.743±0.096
    CT   6 0.797±0.117
    CC   0 -
    pa -
    pb 0.20
rs12444338
    GG 47 0.730±0.089
    GT 30 0.781±0.090
    TT   6 0.691±0.149
    pa 0.15
    pb   0.02*
rs72807847
    AA 82 0.745±0.098
    GA   1 0.819±0.063
    GG   0 -
    pa -
    pb 0.29
rs6565105
    GG 31 0.739±0.099
    GA 37 0.755±0.097
    AA 15 0.741±0.099
    pa 0.79
    pb 0.78
rs1048612
    GG 54 0.733±0.097
    GA 21 0.767±0.107
    AA   7 0.789±0.033
    pa   0.02*
    pb 0.22
IMT, intima-media thickness; SNP, single nucleotide polymorphism. 
ap value of recessive model; bp value of additive model. 
Values are median (interquartile range) or mean±SD.
*p<0.05.
CDH13 Variants and Cardiovascular Traits
Yonsei Med J   http://www.eymj.org   Volume 54   Number 6   November 2013 1311
are be correlated with the studied variants or evaluated phe-
notypes. However, adiponectin values may be a good candi-
date to explain the link between the studied variants and car-
diometabolic phenotypes. Finally, we assessed carotid IMT 
in a group of our subjects, and certain analyses on the vari-
ants and IMT might not have obtained statistical signifi-
cance. 
In conclusion, our study provides evidence that CDH13 
variants may be associated with metabolic traits and carotid 
atherosclerosis in Koreans. Our study shows the multifaceted 
effects of CDH13 variants on metabolic and vascular risk. 
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